Clinical Trials List
2022-05-02 - 2026-09-30
Phase III
Recruiting6
xxxxxx
-
Trial Applicant
GEORGE CLINICAL ASIA PACIFIC LIMITED
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/11/13
Investigators and Locations
Co-Principal Investigator
- I-jen Chiu Division of Nephrology
- Chia-Te Liao Division of Nephrology
- I-WEN WU Division of Nephrology
- Mei-Yi Wu Division of Nephrology
- Li-Yee Hong Division of Nephrology
- Cai-Mei Zheng Division of Nephrology
- Yu-Wei Chen Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jin-Bor Chen Division of Nephrology
- 許淳惟 Division of Nephrology
- 許百慶醫師 Division of Nephrology
- 李隆志 Division of Nephrology
- 邱鼎育 Division of Nephrology
- Wen-Chin Lee Division of Nephrology
- 黃鏘錡 Division of Nephrology
- 楊智超 Division of Nephrology
- 邱千華 Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- SHUEI-LIONG LIN Division of Nephrology
- 黃道民 Division of Nephrology
- VIN-CENT Wu Division of Nephrology
- 楊紹佑 Division of Nephrology
- CHUN-FU LAI Division of Nephrology
- 陳怡婷 Division of Nephrology
- YU-HSIANG CHOU Division of Nephrology
- Yung-Ming Chen Division of Nephrology
- - - Division of Nephrology
- FAN-CHI CHANG Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Sibeprenlimab (VIS649)
Active Ingredient
Sibeprenlimab (VIS649)
Dosage Form
230
Dosage
200 mg/mL
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
470 participants
